Scholar Rock Holding Corporation logo SRRK - Scholar Rock Holding Corporation

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 12
HOLD 0
SELL 0
STRONG
SELL
0
| PRICE TARGET: $59.17 DETAILS
HIGH: $65.00
LOW: $55.00
MEDIAN: $59.00
CONSENSUS: $59.17
UPSIDE: 22.94%

About Scholar Rock Holding Corporation (https://scholarrock.com)

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Key Executives

NAME TITLE DOB SALARY
David L. Hallal Chief Executive Officer & Chairman of the Board 1966 $3,157,439 USD
Akshay K. Vaishnaw President of R&D, Member of Scientific Advisory Board and Director 1963 $2,833,966 USD
Akshay Krishnadas Vaishnaw President of R&D, Member of Scientific Advisory Board and Director 1963 $2,833,966 USD
Robert Keith Woods Chief Operating Officer 1968 $1,107,060 USD
Vikas Sinha CFO & Treasurer 1963 $1,063,909 USD
Jing L. Marantz Chief Medical Officer 1965 $755,185 USD
Mo Qatanani Chief Scientific Officer 1973 $704,681 USD
Junlin General Counsel & Corporate Secretary 1979 $563,729 USD
Caryn Parlavecchio Chief Human Resources Officer 1972
Erin Moore Interim Principal Financial & Accounting Officer 1975
Lisa Amaya Price Senior Vice President of Human Resources
Lisa Wyman Chief Technical & Quality Officer 1978
Rebecca McLeod Chief Brand Officer & GM of U.S.
Rushmie Nofsinger Vice President of Corporate Affairs & Investor Relations
Ryan Iarrobino Senior Vice President of Clinical Development & Operations

Company Peers

Peer analysis pending, check back in 1-2 minutes.